Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Respiratory Restriction Leaded by Conventional or Minimally Invasive Sugical Repair of Oesophageal Atresia in Children (RestriMIS2)

12. november 2026 oppdatert av: University Hospital, Angers

Assessment of Respiratory Restriction Caused by Chest Wall Abnormalities Following Conventional or Minimal Invasive Surgical Repair of Type III Esophageal Atresia in School Age Children

Children born with esophageal atresia need surgery shortly after birth. For many years, the standard operation was a thoracotomy, an opening in the chest that can sometimes lead to changes in the shape of the chest wall. Although these changes are visible on X rays, doctors still do not fully understand how much they affect breathing later in childhood. A newer, less invasive technique called thoracoscopy uses small incisions and appears to cause fewer chest deformities, but its impact on lung function has not yet been clearly established.

This study aims to compare the breathing capacity of children aged 6 to 9 who were operated on using either thoracotomy or thoracoscopy. The main question is whether one group is more likely to develop restrictive lung syndrome, a condition in which the lungs cannot expand normally. To answer this, the study relies on lung function tests and chest X rays performed during routine follow up visits.

Beyond this primary goal, the study also examines other possible breathing problems, the presence of chest wall abnormalities, and factors that might influence lung health, such as nutrition, physical activity, associated malformations, and overall quality of life.

A total of at least 360 children across France will participate. They are identified through national registries and invited during scheduled follow up consultations.

Studieoversikt

Studietype

Observasjonsmessig

Registrering (Antatt)

360

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Amiens, Frankrike, 80054
        • CHU Amiens, Département de Pédiatrie, centre d'activité "chirurgie pédiatrique viscérale"
        • Ta kontakt med:
        • Hovedetterforsker:
          • Philippe BUISSON, MD
      • Angers, Frankrike, 49933
        • CHU Angers, Service Urgences, Médecine, Psychiatrie et Chirurgie Pédiatriques
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • francoise SCHMITT, MD
      • Clermont-Ferrand, Frankrike, 63003
        • CHU Clermont-Ferrand, Service de pédiatrie générale et multidisciplinaire
        • Ta kontakt med:
        • Hovedetterforsker:
          • Carole EGRON, MD
      • Dijon, Frankrike, 21000
        • CHU Dijon, Service de chirurgie pédiatrique
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michel FRANCOIS, MD
      • Grenoble, Frankrike, 38700
        • CHU Grenoble, Service de chirurgie pédiatrique
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pierre-Yves RABATTU, MD
      • Le Kremlin-Bicêtre, Frankrike, 94275
        • Hôpital Bicêtre, AP-HP, Chirurgie Viscérale Pédiatrique
        • Ta kontakt med:
        • Hovedetterforsker:
          • Khadidja KHADIR, MD
      • Lyon, Frankrike, 69677
        • Hospices Civils de Lyon, Service d'Hepato-Gastroentérologie et Nutrition Pédiatrique
        • Ta kontakt med:
        • Hovedetterforsker:
          • Nicolas CARON, MD
      • Nantes, Frankrike, 44093
        • CHU Nantes, Hôpital Mère-Enfant, Service de Chirurgie Infantile
        • Ta kontakt med:
        • Hovedetterforsker:
          • Audrey GUINOT, MD
      • Paris, Frankrike, 75015
        • Hôpital Necker Enfants Malades, AP-HP, Service de Pneumologie et Allergologie Pédiatriques
        • Ta kontakt med:
        • Hovedetterforsker:
          • Rola ABOU TAAM, MD
      • Strasbourg, Frankrike, 67098
      • Toulouse, Frankrike, 31059
        • CHU Toulouse, Service de Chirurgie Viscérale Pédiatrique
        • Ta kontakt med:
        • Hovedetterforsker:
          • Aurelie LE MANDAT, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

6 år til 10 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

Eligible patients in both groups are mainly identified through the national esophageal atresia registry (RENATO, CRACMO, CHU Lille).

Beskrivelse

For thoracoscopy group:

Inclusion Criteria:

  • Child operated on by thoracoscopy for type 3 AO (excluding long gap) according to Ladd's classification
  • Child aged 6 to 10 years old
  • Consent from parents (or legal guardians) and the child's agreement to participate in the study

Exclusion Criteria:

  • Heart or lung malformation diagnosed at birth and requiring surgery
  • Conversion from thoracoscopy to thoracotomy during the procedure
  • Child who has had more than one thoracic surgery (reoperation for AO, other reasons for thoracic surgery including heart surgery)
  • For Thoracotomy group*:

Inclusion Criteria :

--Child operated on by thoracotomy for type 3 AO (excluding long gap) according to the Ladd classification

  • Child aged 6 to 10 years old
  • Consent from parents (or legal guardians) and the child's agreement to participate in the study

Exclusion Criteria:

  • Heart or lung malformation diagnosed at birth and requiring surgery
  • Child who has had more than one thoracic surgery (reoperation for AO, other reason for thoracic surgery including heart surgery)
  • Child operated on for type 3 AO via thoracotomy (excluding long gap) according to Ladd's classification

For each patient who underwent thoracoscopic surgery included in the study, two patients who had thoracotomy, matched according to known or suspected confounding factors for restrictive syndromes from the RestriMIS1 (NCT04136795) study**, will be included.

*It's possible that some children had multiple consecutive surgeries. In those cases, if one of the procedures was a thoracotomy, the children will be classified in the thoracotomy group (the more major surgery).

**Prematurity, birth weight, presence of tracheomalacia, and GERD during the neonatal period (clinically and/or on additional tests)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
thoracoscopy group

minimally invasive surgical approach

thoracotomy arm

conventionnal surgical approach

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
to assess the presence of a restrictive lung syndrome in patients with type 3 esophageal atresia (EA) depending on the type of surgical approach used (conventional or minimally invasive).
Tidsramme: Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)

Rate of restrictive syndrome according to the type of surgical approach (conventional or minimally invasive), defined by spirometry data: FEV1/FVC > -1.64 Z-score and FVC < -1.64 Z-score, according to the ATS/ERS-GLI (American Thoracic Society & European Respiratory Society - Global Lung Initiative) recommendations published in 2012 (Quanjer) and reviewed en 2022.

Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
to evaluate the importance of restrictive syndrome
Tidsramme: importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)

The importance of restrictive syndrome is classified into 3 levels: mild restrictive syndrome [-1.64 > z-score ≥ -2.5], moderate [-2.5 > z-score ≥ -4.0], or severe [-4.0 > z-score]).

importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)
Looking for other respiratory parameters
Tidsramme: the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation

Other respiratory changes are examined by measuring other respiratory parameters (forced vital capacity, FEF 25-75, Tiffeneau ratio, reversibility), which help highlight obstructive or mixed syndromes (FEV1/FVC < -1.64 and FVC < -1.64 z-score) when present

the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation
to assess the link between chest skeletal abnormalities found on chest X-rays and lung impact
Tidsramme: until spirometry is completed, within a maximum period of 2 years

The following factors are considered when estimating the risk of association with or without a restrictive syndrome (history data like prematurity or types of malformations associated with AO III, surgical and medical care data in the neonatal period and childhood, growth data at one year and at 6-10 years), lung care, physical activity, the PedsQL score (for children aged 6 to 10), and responses to the EA-QoL questionnaire (for children aged 8 to 10).

until spirometry is completed, within a maximum period of 2 years
rate of postoperative complications and any necessary reoperations
Tidsramme: up to 2 years after the multidisciplinary consultation

The rate of postoperative complications is assessed by type of surgery as well as any necessary follow-up surgeries.

up to 2 years after the multidisciplinary consultation
Respiratory-related quality of life during childhood
Tidsramme: up to 2 years after the multidisciplinary consultation

It will be estimated through both need for lung care, physical activity, PedsQL score (for children aged 6 to 10), and EA-QoL questionnaire (for children aged 8 to 10).

up to 2 years after the multidisciplinary consultation
to assess the existence of a cause-and-effect link between the restrictive syndrome and the surgical technique used
Tidsramme: through study completion, within a maximum of 24 months

The acceptability of the existence of a causal link is assessed using sensitivity analysis, which estimates how robust the results are while taking into account missing data and different clinical scenarios (including a per-protocol analysis in addition to the intention-to-treat analysis).

through study completion, within a maximum of 24 months
to assess the mortality rate
Tidsramme: through study completion, an average 7 years

The death rate for each surgery group will be described based on the follow-up in the study, that is, the date of the surgery (combined data for all patients in the registry).

through study completion, an average 7 years
Looking for lung volumes variations
Tidsramme: the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation

Lung volume variations will be measured by dynamic respiratory MRI data

the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

2. desember 2026

Primær fullføring (Antatt)

2. desember 2032

Studiet fullført (Antatt)

2. desember 2032

Datoer for studieregistrering

Først innsendt

22. september 2026

Først innsendt som oppfylte QC-kriteriene

12. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere